Pure Global: USA MedTech's Risky QMS Shift Beyond ISO 13485

The US FDA is making its biggest change to quality system regulations in a generation, harmonizing with the global ISO 13485 standard. This shift, mandated by the new Quality Management System Regulation (QMSR), presents both opportunities for streamlined global compliance and significant hidden risks for unprepared manufacturers. Many global companies with existing ISO 13485 certification are operating under the dangerous assumption that they are already compliant. We explore a real-world case where a European company, despite being fully CE-marked, discovered critical gaps in their risk management and supplier controls that would have resulted in serious FDA non-compliance, jeopardizing their US market access. This episode breaks down the specific differences and what you need to do now. Key Takeaways: - Why is the FDA's new QMSR more than just a copy-paste of ISO 13485? - What are the top three "hidden gaps" between your current ISO certificate and full FDA compliance? - How does the new rule fundamentally change the approach to risk management for devices sold in the US? - What specific records and procedures will FDA inspectors scrutinize most under the new QMSR? - Is your management review process truly ready for the new, stricter requirements? - How can you leverage this transition to streamline your global quality strategy instead of just adding paperwork? - What are the critical FDA "carve-outs" in the final rule that most consultants are not talking about? Contact us at [e-mail] or visit https://pureglobal.com/ or visit https://pureglobal.ai/ for FREE AI tools and free medical device database.